Content
Search
Navigation
Sitemap

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Late-stage clinical companies companies
Autolus Therapeutics
Beacon Therapeutics
all Clinical companies companies
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
all Pre-clinical companies companies
Resolution Therapeutics
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Slingshot Therapeutics

10.12.24

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Operating News
Pre-clinical companies
Resolution Therapeutics

19.11.24

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

Pre-clinical companies
Resolution Therapeutics

11.11.24

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD 2024

Pre-clinical companies
Resolution Therapeutics

03.10.24

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

Pre-clinical companies
Resolution Therapeutics

01.10.24

Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024

Pre-clinical companies
Resolution Therapeutics

27.06.24

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001

Pre-clinical companies
Resolution Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

Copyright © Syncona 2025
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern slavery statement

Syncona Limited is registered in Guernsey no. 55514, registered office Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

threethirty.studio

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

GBX 93.10

Change: +0.10 (+0.11%)

Search

Search